Search Clinical Trials
Sponsor Condition of Interest |
---|
Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines
East Carolina University
Coronavirus
The COVID-19 pandemic has highlighted deleterious US health inequities. Specifically,
African Americans, Latinos, and Native Americans have and continue to shoulder a greater
burden of COVID-19 infections and deaths in the US. In addition to existing racial and
ethnic disparities are rural health... expand
The COVID-19 pandemic has highlighted deleterious US health inequities. Specifically, African Americans, Latinos, and Native Americans have and continue to shoulder a greater burden of COVID-19 infections and deaths in the US. In addition to existing racial and ethnic disparities are rural health and regional disparities. Given the disproportionate impact of disease in US communities of color and also in rural and southern regions of the US, there is no doubt that these at-risk subgroups will continue to experience higher rates of coronavirus-related mortality as well as other long-term health outcomes as compared to other US populations. It is unknown how healthcare providers and other key at-risk subgroups within the US will receive COVID-19 vaccines. For success in immunizations, the US will need to reach their most at-risk and vulnerable populations. In addition to at-risk populations, a successful immunization strategy will involve engaging providers to support clear, consistent, and strong vaccine recommendation. It is critical to build vaccine trust, confidence, and overall acceptance of COVID-19 vaccines among healthcare providers and key at-risk subgroups, especially given the accelerated production timeline of these vaccines. Likewise, tailored vaccine messaging for key subgroups is vital in achieving vaccine confidence and trust. The proposed study will explore perceptions, confidence, trust, and uptake of potential COVID-19 vaccines among healthcare providers (nurses and doctors) and key at-risk population subgroups (minority populations living in the rural south) and will develop and test vaccine messaging that boosts vaccine confidence and trust among these key at-risk subgroups. Type: Observational Start Date: Feb 2021 |
Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator...
Northwell Health
ARDS, Human
Covid19
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from
observational reports from around the world. This has ranged from 44% (28 day mortality)
in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32%
(all-cause 28 day mortality) in Spain. Predictive... expand
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Predictive models have identified risk factors for COVID-19 hospitalized patients' mortality to include male sex, obesity, age, obesity, comorbidities including chronic lung disease and hypertension, as well as biomarkers including high levels of D-Dimer, LDH and CRP. In addition, practice patterns, such as drugs that were administered, timing of mechanical ventilation and adherence to established lung protective ventilation protocols are known to be variable across sites and have changed over time. The investigators propose to analyze outcomes for patients with COVIDARDS within the NorthCARDS dataset (a dataset of over 1500 patients with COVID-19 related ARDS across the Northwell Health System in the NYC metropolitan region and Long Island, NY) to understand differences in hospital survival and in the time to liberation from mechanical ventilation, specifically looking at the associations between baseline patient factors, changes in biomarkers, respiratory function and hemodynamics over time, and treatments administered. The analyses will be based on three hypotheses: H.1. Worsening trajectories of: oxygenation index (OI), respiratory system compliance (C), and inflammatory markers will be associated with lower hospital survival. H.2. Higher duration of deep sedation and paralytics will be associated with greater time to liberation from mechanical ventilation. This risk will be increased in patients with worsening trajectories of OI, C, and inflammatory markers over time. H.3. Type of mechanical ventilator, specifically the time on portable mechanical ventilator, is associated with hospital mortality and with inability to liberate from mechanical ventilator despite controlling for risk factors of changes in OI, C and Inflammatory markers over time, and the use of paralytics and deep sedation. Type: Observational [Patient Registry] Start Date: Jan 2021 |
Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods
Columbia University
Covid19
Vaccine Acceptability
The overall purpose of this study is to address the factors associated with an
individual's personal willingness to get the vaccine and attitudes about potential public
policy approaches to implementation of a Coronavirus Disease 2019 (COVID-19) vaccine.
Additionally, to evaluate how these attitudes... expand
The overall purpose of this study is to address the factors associated with an individual's personal willingness to get the vaccine and attitudes about potential public policy approaches to implementation of a Coronavirus Disease 2019 (COVID-19) vaccine. Additionally, to evaluate how these attitudes change over time. The 1200 participants will be recruited by Ipsos (Ipsos KnowledgePanel®) from their nationally representative panel to participate in a survey at Time 1 and 1 year later. The information collected will include demographics, health status, household composition, experiences with COVID-19, attitudes about vaccines in general, COVID-19 vaccine specific attitudes, willingness to get a COVID-19 vaccine acceptability, and attitudes regarding COVID-19 vaccine mandates. The investigators anticipate that those who live in urban areas and who are older, have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID-19, and have generally positive attitudes about vaccines will be more willing to get a vaccine. The primary reasons for willingness will be personal safety and desire to return to normal activities. The investigators also anticipate that those who vary on socio-demographics (e.g., live in urban areas, have more liberal political views), have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID- 19, and have generally positive attitudes about vaccines will be more supportive of mandatory vaccination strategies. The investigators anticipate that attitudes will change over time in response to the current status of the pandemic and of available data about the vaccine's efficacy and safety. Type: Observational Start Date: Apr 2021 |
Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test
LumiraDx UK Limited
Covid19
Evaluation of the agreement between fingerstick samples, venous blood, serum and plasma
samples when using the LumiraDx SARS-CoV-2 Ab Test against the reference method, using
standard qualitative comparison techniques. expand
Evaluation of the agreement between fingerstick samples, venous blood, serum and plasma samples when using the LumiraDx SARS-CoV-2 Ab Test against the reference method, using standard qualitative comparison techniques. Type: Interventional Start Date: Jul 2020 |
FEnofibRate as a Metabolic INtervention for COVID-19
University of Pennsylvania
Covid19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoC-2), the virus responsible
for coronavirus disease 2019 (COVID-19), is associated with a high incidence of acute
respiratory distress syndrome (ARDS) and death. Aging, obesity, diabetes, hypertension
and other risk factors associated with... expand
The severe acute respiratory syndrome coronavirus 2 (SARS-CoC-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with a high incidence of acute respiratory distress syndrome (ARDS) and death. Aging, obesity, diabetes, hypertension and other risk factors associated with abnormal lipid and carbohydrate metabolism are risk factors for death in COVID-19. Recent studies suggest that COVID-19 progression is dependent on metabolic mechanisms. Moreover, gene expression analyses in cultured human bronchial cells infected with SARS-CoV-2 and lung tissue from patients with COVID-19, indicated a marked shift in cellular metabolism, with excessive intracellular lipid generation. In this cell culture system, fenofibrate (a widely available low-cost generic drug approved by the FDA and multiple other regulatory agencies around the world to treat dyslipemias) at concentrations that can be achieved clinically, markedly inhibited SARS-CoV-2 viral replication. Fenofibrate also has immunomodulatory effects that may be beneficial in the setting of COVID-19. The aim of this trial is to assess the clinical impact of fenofibrate (145 mg/d of Tricor or dose-equivalent preparations for 10 days, with dose adjustment in chronic kidney disease ([CKD]) to improve clinical outcomes in patients with COVID-19. Type: Interventional Start Date: Aug 2020 |
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Ridgeback Biotherapeutics, LP
SARS-CoV 2
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess
the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized
Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. expand
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. Type: Interventional Start Date: Jun 2020 |
CareSuperb COVID-19 Antigen Test Usability
AccessBio, Inc.
COVID-19
The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen
Home Test in Home Use. expand
The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test in Home Use. Type: Interventional Start Date: Nov 2022 |
COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation
New Day Diagnostics
SARS-CoV-2 Infection
COVID-19
SARS-CoV-2 rapid antigen over the counter clinical performance evaluation. expand
SARS-CoV-2 rapid antigen over the counter clinical performance evaluation. Type: Interventional Start Date: Aug 2022 |
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People...
Pfizer
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19)
Immunocompromised
Hospitalization
Child, Hospitalized
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With
Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes
who are Hospitalized Due to Severe COVID-19 expand
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19 Type: Interventional Start Date: Dec 2022 |
A CHW Intervention to Identify and Decrease Barriers to COVID 19 Testing & Vaccination
Charles Drew University of Medicine and Science
Vaccine Hesitancy
COVID-19 Testing
Community Health Workers
The objective of this study is to compare the results of a COVID-19 specific curriculum
led by LACDHS Community Health Workers (CHWs) from these same communities of safety-net
patients to effectively increase COVID-19 testing and vaccination for individual
patients, and to facilitate needed healthcare... expand
The objective of this study is to compare the results of a COVID-19 specific curriculum led by LACDHS Community Health Workers (CHWs) from these same communities of safety-net patients to effectively increase COVID-19 testing and vaccination for individual patients, and to facilitate needed healthcare in a timely manner for the safety net health system, and to develop a sustained public health presence in these communities to build trust and preparedness for critical COVID-19 related future needs. Type: Interventional Start Date: Oct 2022 |
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019...
Shenyang Tonglian Group CO., Ltd
Coronavirus Disease 2019
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in
patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infection. expand
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Type: Interventional Start Date: Mar 2021 |
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19...
Genentech, Inc.
COVID-19 Pneumonia
This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ)
compared with a placebo in combination with standard of care (SOC) in hospitalized
participants with COVID-19 pneumonia, and b) include an optional long-term extension for
eligible participants to explore the long-term... expand
This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an optional long-term extension for eligible participants to explore the long-term sequelae of resolved COVID-19 pneumonia. Type: Interventional Start Date: May 2020 |
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
Black Tie Medical, Inc.
Pulmonary Alveolar Proteinosis
COPD
Idiopathic Pulmonary Fibrosis
Viral Pneumonia
Coronavirus Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including
Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging
pulmonary alveolar structure and functionality. A short review includes:
- Early December, 2019 - A pneumonia of unknown cause... expand
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs. Type: Interventional Start Date: Mar 2020 |
LAEH Formulation Nasal Spray to Reduce Viral Load
Salvacion USA Inc.
Coronavirus Disease
The Covixyl-V LAEH Nasal Spray's safety and efficay is clinically tested for use in
subjects with COVID-19 infection.
A randomized, double-blind, multi-center study is conducted to evaluate the efficacy and
safety of ethyl lauroyl arginate hydrochloride (LAEH) formulation versus a matching
placebo... expand
The Covixyl-V LAEH Nasal Spray's safety and efficay is clinically tested for use in subjects with COVID-19 infection. A randomized, double-blind, multi-center study is conducted to evaluate the efficacy and safety of ethyl lauroyl arginate hydrochloride (LAEH) formulation versus a matching placebo formulation administered as a nasal spray to reduce viral load from nasal area of subjects with coronavirus disease 2019 (COVID-19). Type: Observational [Patient Registry] Start Date: May 2021 |
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults...
Pfizer
COVID-19
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and
effective for the treatment of adults who are ill with COVID-19 and do not need to be in
the hospital, but are at an increased risk of developing severe illness. Throughout the
study period, provision will be made... expand
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks. Type: Interventional Start Date: Jul 2021 |
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
Providence Health & Services
SARS-CoV-2
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12,
(electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the
combination of electroporated IL-12p70 plasmid. expand
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid. Type: Interventional Start Date: Dec 2020 |
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
AgelessRx
Covid19
Long COVID-19
Post-COVID-19 Syndrome
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with
post-COVID-19 syndrome. expand
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome. Type: Interventional Start Date: Jan 2021 |
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir
(MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to
placebo as assessed by the rate of sustained recovery through Day 29. expand
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29. Type: Interventional Start Date: Oct 2020 |
Nebulised Heparin in Patients With Severe COVID-19
Australian National University
Covid19
Respiratory Failure
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with
COVID-19 Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective
collaborative individual patient data analysis of randomised controlled trials and early
phase studies. Individual studies are being... expand
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective collaborative individual patient data analysis of randomised controlled trials and early phase studies. Individual studies are being conducted in multiple countries, including Australia, Ireland, the USA, and the UK. Mechanically ventilated patients with confirmed or strongly suspected SARS-CoV-2 infection, hypoxaemia and an acute pulmonary opacity in at least one lung quadrant on chest X-ray, will be randomised to nebulised heparin 25,000 Units every 6 hours or standard care (open label studies) or placebo (blinded placebo controlled studies) for up to 10 days while mechanically ventilated. All trials will collect a minimum core dataset. The primary outcome for the meta-trial is ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation. Individual studies may have additional outcomes. Type: Interventional Start Date: Nov 2020 |
Tafenoquine in Patients With Mild to Moderate COVID-19
60 Degrees Pharmaceuticals LLC
COVID 19 Disease
A clinical study to assess the efficacy and safety of oral tafenoquine compared to
placebo in patients with mild to moderate COVID 19 disease. expand
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease. Type: Interventional Start Date: Feb 2021 |
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia
Nature Cell Co. Ltd.
Covid19 Pneumonia
This study is an open-label, single-arm study to evaluate the safety and efficacy of
Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients
with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the
data management team confirms all individual... expand
This study is an open-label, single-arm study to evaluate the safety and efficacy of Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis. Type: Interventional Start Date: Oct 2022 |
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
Bellerophon Pulse Technologies
COVID-19
Coronavirus
Coronavirus Infection
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of
pulsed inhaled iNO compared to placebo in subjects with COVID-19. expand
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19. Type: Interventional Start Date: Jul 2020 |
Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA
Children's Hospital Medical Center, Cincinnati
COVID-19
SARS-CoV 2
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic
and is associated with significant morbidity and mortality. The mortality rate for
COVID-19 patients admitted to an intensive care unit (ICU) who require mechanical
intubation is approximately 75%. While the... expand
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic and is associated with significant morbidity and mortality. The mortality rate for COVID-19 patients admitted to an intensive care unit (ICU) who require mechanical intubation is approximately 75%. While the pathophysiology of severe COVID-19 has yet to be fully understood, it is possible that a combination of high viral loads and an overactive dysregulated inflammatory response may contribute. Therefore, the clearance of SARS-CoV-2 virus and cytokines could provide a more opportunistic environment for the innate immune system to clear the virus and establish lasting immunity. The Seraph®-100 Microbind® Affinity Blood Filter (Seraph®-100) is an extracorporeal broad-spectrum sorbent hemoperfusion filter for removing virus and cytokines from the blood. The FDA authorized an Emergency Use Authorization (EUA) for treatment of severe COVID-19 with the Seraph®-100. As part of the EUA, this registry study will collect de-identified data to assess safety and efficacy on the use of Seraph®-100 Microbind® Affinity Blood Filter in the treatment of COVID-19 patients. Type: Observational [Patient Registry] Start Date: Jun 2020 |
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Karyopharm Therapeutics Inc
Coronavirus Infection
The main purpose of this study is to evaluate the activity of low dose oral selinexor
(KPT-330) and to evaluate the clinical recovery, the viral load, length of
hospitalization and the rate of morbidity and mortality in participants with severe
COVID-19 compared to placebo. The study had 2 arms and... expand
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time and across regions of the world. Type: Interventional Start Date: Apr 2020 |
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332...
Pfizer
Healthy Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period
crossover study to evaluate the effect of high-fat meal on the relative bioavailability
of PF-07321332 boosted with ritonavir following single dose oral administration of
PF-07321332 in combination with ritonavir... expand
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following single dose oral administration of PF-07321332 in combination with ritonavir using 150 mg tablet formulation of PF-07321332 in healthy adult participants. Type: Interventional Start Date: Nov 2021 |
- Previous
- Next